PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics is holding its 2026 Annual Meeting of Stockholders virtually on June 2, 2026 at 9:00 a.m. Eastern Time via webcast at www.virtualshareholdermeeting.com/PTCT2026. Stockholders will vote on electing four Class I directors to terms ending in 2029, ratifying Ernst & Young LLP as independent auditor, and approving an advisory "say‑on‑pay" resolution for named executive officer compensation.
The record date is April 10, 2026, with 82,911,783 common shares outstanding, each entitled to one vote. The board reports that all directors except the CEO are independent, maintains a classified board structure, and emphasizes ESG, employee development, and diversity. Ernst & Young LLP billed audit and related services totaling $2.81 million in 2025, and the audit committee recommends ratification.
PTC Therapeutics executive Mark Elliott Boulding exercised stock options and sold shares in a pre-planned trade. He exercised options to acquire 2,265 shares of Common Stock at an exercise price of $39.42 per share and received 2,265 shares.
On the same date, he sold 822 shares at a weighted average price of $68.91 per share and 1,443 shares at a weighted average price of $69.75 per share, pursuant to a Rule 10b5-1 trading plan. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
PTC Therapeutics, Inc. executive Lee Scott Golden reported an automatic sale of 829 shares of Common Stock at $67.99 per share. According to the disclosure, these shares were sold pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 2,100 restricted stock units (RSUs) from an April 24, 2023 grant of 8,400 RSUs. Following this tax-related sale, Golden directly holds 79,115 shares of PTC Therapeutics common stock, so the transaction represents a small portion of his overall reported holdings.
PTCT notice under Rule 144 reporting proposed sale of 2,265 shares of Common Stock by issuance/option proceeds on 04/06/2026. The filing also lists multiple prior disposals by Mark Boulding in early 2026, including sales of 1,739, 4,879, 4,033, 2,314, 2,813, 3,081, and 3,019 shares on specific dates.
PTC Therapeutics, Inc. reported that Chief Technical Operations Officer Neil Gregory Almstead sold a total of 52,003 shares of common stock in open‑market transactions on 2026-04-01 at prices around $69 per share.
After these sales, he directly holds 60,137 shares of PTC Therapeutics common stock and indirectly holds 2,737 shares through his spouse. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
PTCT submitted a Form 144 notice reporting proposed resale activity in its Common Stock. The filing lists 829 shares tied to a restricted stock vesting on 04/01/2026 as securities to be sold. The filing also itemizes open-market dispositions by Lee S. Golden during the prior three months: 1,340, 642, 866, 2,484, and 10,000 shares with corresponding proceeds shown on the form.
PTCT insiders reported multiple restricted-stock vesting events and subsequent Rule 144 sales. The excerpt lists scheduled restricted-stock vesting entries across 2016–2025 and shows recent open-market sales by Neil G. Almstead and Zheng Y. Almstead on specific dates in 2026 with per-trade share counts and proceeds.
PTC Therapeutics Inc: The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of PTC Therapeutics common stock. The filing states Vanguard disaggregated certain subsidiaries after an internal realignment effective January 12, 2026 in reliance on SEC Release No. 34-39538. The amendment is signed by Ashley Grim on 03/27/2026.
PTC Therapeutics director Jessica Caroline Chutter received new equity awards. On March 24, 2026, she was granted stock options for 3,475 and 2,896 shares of common stock at an exercise price of $64.54 per share, expiring on March 23, 2036.
She also received 4,000 restricted stock units that vest in three equal annual installments starting March 24, 2027, and 3,333 restricted stock units that vest with 1,000 shares on June 2, 2026 and 2,333 shares on January 2, 2027. All transactions reflect compensation-related grants rather than open-market purchases or sales.